ε-Poly-L-Lysine/plasmid DNA nanoplexes for efficient gene delivery in vivo

被引:57
|
作者
Mandal, Haimanti [1 ]
Katiyar, Sameer S. [1 ]
Swami, Rajan [1 ]
Kushwah, Varun [1 ]
Katare, Parmeshwar B. [2 ]
Meka, Anand Kumar [3 ]
Banerjee, Sanjay K. [2 ]
Popat, Amirali [3 ,4 ]
Jain, Sanyog [1 ]
机构
[1] NIPER, Dept Pharmaceut, Ctr Pharmaceut Nanotechnol, Sect 67, Mohali 160062, Punjab, India
[2] Translat Hlth Sci & Technol Inst, Drug Discovery Res Ctr, Faridabad 121001, India
[3] Univ Queensland, Sch Pharm, Brisbane, Qld 4072, Australia
[4] Univ Queensland, Mater Res Inst, Inflammatory Dis Biol & Therapeut Grp, Translat Res Inst, 37 Kent St, Woolloongabba, Qld 4102, Australia
基金
英国医学研究理事会;
关键词
Gene expression; Polyplex; Transfection efficiency; Cytotoxicity; PLASMID DNA; L-LYSINE; POLYLYSINE; POLYCATION; POLYPLEXES; VECTORS; THERAPY; NANOPARTICLES; PARTICLES; SYSTEMS;
D O I
10.1016/j.ijpharm.2018.03.021
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The present work addresses the development and characterization of epsilon-Poly-L-Lysine/pDNA polyplexes and evaluation for their improved transfection efficacy and safety as compared to polyplexes prepared using Poly-L-Lysine and SuperFect (R). Self-assembling polyplexes were prepared by varying the N/P ratio to obtain the optimum size, a net positive zeta potential and gel retardation. The stability in presence of DNase I and serum was assured using gel retardation assay. Their appreciable uptake in MCF-7 and 3.5, 3.79 and 4.79-fold higher transfection compared to PLL/pDNA polyplexes and 1.60, 1.53 and 1.79-fold higher transfection compared to SuperFect (R)/pDNA polyplexes in MCF-7, HeLa and HEK-293 cell lines respectively, affirmed the enhanced transfection of epsilon-PLL/pDNA polyplexes which was well supported with in vivo transfection and gene expression studies. The < 8% in vitro hemolysis and > 98% viability of MCF-7, HeLa and HEK-293 cells in presence of epsilon-PLL/pDNA polyplexes addressed their safety, which was also ensured using in vivo toxicity studies, where hemocompatibility, unaltered levels of biochemical markers and histology of vital organs confirmed epsilon-PLL to be an effective and safer alternative for non-viral genetic vectors.
引用
收藏
页码:142 / 152
页数:11
相关论文
共 50 条
  • [21] POLY-L-LYSINE, A NUTRITIONAL SOURCE OF LYSINE
    NEWMAN, CW
    JAYNES, JJ
    SANDS, DC
    FEDERATION PROCEEDINGS, 1981, 40 (03) : 848 - 848
  • [22] FRACTIONATION OF DNA ON COLUMNS OF POLY-L-LYSINE SUPPORTED ON KIESELGUHR
    HELLEINE.CW
    CANADIAN JOURNAL OF BIOCHEMISTRY, 1969, 47 (12): : 1199 - &
  • [23] CALORIMETRIC STUDIES OF INTERACTION BETWEEN DNA AND POLY-L-LYSINE
    KLUMP, H
    BIOPHYSICAL CHEMISTRY, 1976, 5 (03) : 363 - 367
  • [24] Evaluation and comparison of cytotoxicity, genotoxicity, and apoptotic effects of poly-l-lysine/plasmid DNA micro- and nanoparticles
    Alinejad-Mofrad, E.
    Malaekeh-Nikouei, B.
    Gholami, L.
    Mousavi, S. H.
    Sadeghnia, H. R.
    Mohajeri, M.
    Darroudi, M.
    Oskuee, R. K.
    HUMAN & EXPERIMENTAL TOXICOLOGY, 2019, 38 (08) : 983 - 991
  • [25] Alginate/Poly-L-Lysine Microparticles for the Intestinal Delivery of Antisense Oligonucleotides
    María González Ferreiro
    Lloyd G. Tillman
    Gregory Hardee
    Roland Bodmeier
    Pharmaceutical Research, 2002, 19 : 755 - 764
  • [26] Alginate/poly-L-lysine microparticles for the intestinal delivery of antisense oligonucleotides
    Ferreiro, MG
    Tillman, LG
    Hardee, G
    Bodmeier, R
    PHARMACEUTICAL RESEARCH, 2002, 19 (06) : 755 - 764
  • [27] POLY A POLY-L-LYSINE CONFORMATIONAL TRANSITIONS
    DAVIDSON, B
    FASMAN, GD
    FEDERATION PROCEEDINGS, 1969, 28 (02) : 732 - &
  • [28] SINGLE CRYSTALS OF POLY-L-LYSINE
    PADDEN, FJ
    KEITH, HD
    GIANNONI, G
    BIOPOLYMERS, 1969, 7 (05) : 793 - &
  • [29] HYDROLYSIS OF POLY-L-LYSINE BY PRONASE
    SASS, R
    THIEMANN, W
    BIOPOLYMERS, 1973, 12 (03) : 535 - 539
  • [30] Hepotocyte-Directed Gene Delivery Using Targeted Poly-L-Lysine Coated Selenium Nanoparticles
    Naidoo, Shaigan
    Singh, Dhireshan
    Singh, Moganavelli
    MOLECULAR THERAPY, 2020, 28 (04) : 294 - 294